Back to Business
Business
7 August 2026
Cardiac drug developer Braveheart banks more than $382M in IPO
Braveheart is one of five biotechnology firms that made plans to price an IPO this week. They could collectively raise more than $1 billion from public investors.
About this report
Downunder Voices provides an independently written summary and community perspective based on information published by the original source. The original publisher remains responsible for its reporting.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
